A Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: Pregabalin

• Registration Number: NCT01635751
• Lead Sponsor: GL Pharm Tech Corporation

Brief Summary

The purpose of this clinical trial is to compare the pharmacokinetic characteristics of GLA5PR GLARS tablet 150mg and Lyrica Capsule 75mg.

GLA5PR GLARS tablet 150mg is a new once-a-day formulation which is made by GL Pharm Tech corporation.

GLARS(Geometrically Long Absorption Regulated System) is new solution to sustained absorption by extending the absorption Site.

To overcome the shortcomings of the currently existing sustained release drug delivery technologies the investigators have recently developed a novel drug delivery system to enable a drug to be dissolved irrespective of the surrounding environment and further absorbed up to colon. The investigators coined this "Geometrically Long Absorption Regulated System(GLARS)".

Detailed Description

Basically, this system is a triple-layered tablet, comprised of upper and lower layers that swell and draw a sufficient amount of water, plus a highly water - soluble middle layer that rapidly draw water into the tablet core simultaneously.

The water drawn into the tablet (about 3 to 4 times the weight of the tablet itself) functions as an additional media which enables additional and later drug release out of the dosage form. This serves to overcome the shortage of surrounding media that has been reported to be one of the key reasons for malabsorption of a drug in colon.

As the middle layer induces a rapid water draw into the tablet core, the penetrated water also diffuses to the upper and lower layers, which makes the tablet to rapidly swell and controls drug release.

At virtually the same time, the swollen upper and lower layers form to surround a lateral side of the middle layer, which can, in turn, further control drug release.

This relatively rigid swollen matrix structure makes drug release not affected by surrounding mechanical flux, which can provide relatively consistent in vivo drug release irrespective of degree of gastrointestinal motility.

Study Timeline

• Study First Submitted: 2012-07-04
• Study First Submitted QC: 2012-07-09
• Study First Posted: 2012-07-10
• Study Start: 2012-10
• Primary Completion: 2012-11
• Study Completion: 2012-11
• Status Verified: 2013-01
• Last Update Submitted: 2013-01-25
• Last Update Posted: 2013-01-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 30

Inclusion Criteria

• 20~45 years old, Healthy Adult Male Subject
• ≥ 50kg(Body Weight) and Ideal Body Weight ≤ ±20%

Exclusion Criteria

• ALT or AST > 1.25(Upper Normal Range)
• Total Bilirubin > 1.5 (Upper Normal Range)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Lyrica Capsule 75mg(fasted)	Pregabalin	-
GLA5PR GLARS tablet 150mg(after high fat meal)	Pregabalin	-
GLA5PR GLARS tablet 150mg(fasted)	Pregabalin	-

Primary Outcome Measures

Name	Time	Method
Cmax	36hrs	Pharmacokinetic of Pregabalin
Tmax	36hrs	Pharmacokinetic of Pregabalin
AUC0-36h	36hrs	Pharmacokinetic of Pregabalin
AUC0-∞	36hrs	Pharmacokinetic of Pregabalin
CL/F	36hrs	Pharmacokinetic of Pregabalin
Vd/F	36hrs	Pharmacokinetic of Pregabalin
T1/2	36hrs	Pharmacokinetic of Pregabalin

Secondary Outcome Measures

Name	Time	Method
Safety Monitoring	23 days	Adverse Event, Vital sign, 12-lead ECG, Laboratory test

Trial Locations

Locations (1)

The Catholic University of Korea, Seoul St.Mary's Hospital; 🇰🇷 Seochogu, Seoul, Korea, Republic of